|
|
ºÐ°ú | ½Ã°£ | ±³À°ÁÖÁ¦ | ¼º¸í | ¼Ò¼Ó |
---|---|---|---|---|
Ç÷¾×Á¾¾ç 318È£ |
Recent update in the treatment of solid tumors and hematologic malignancies
<ÁÂÀå: ¼Ã¶¿ø>
|
|||
09:45~10:10 | Adult acute lymphoblastic leukemia | ±è´ë¿µ | ¿ï»êÀÇ´ë | |
10:10~10:35 | Chronic lymphocytic leukemia | Á¶¼®±¸ | °¡Å縯ÀÇ´ë | |
10:35~11:00 | Multiple myeloma | ±è±âÇö | ¼º±Õ°üÀÇ´ë | |
<ÁÂÀå: ±è¿È«>
|
||||
08:30~08:55 | Advanced/metastatic non-small cell lung cancer | Á¶º´Ã¶ | ¿¬¼¼ÀÇ´ë | |
08:55~09:20 | Metastatic breast cancer | ÀÓ¼®¾Æ | ¼¿ïÀÇ´ë | |
09:20~09:45 | Metastatic colorectal cancer | ¿À»óö | °í·ÁÀÇ´ë | |
È£Èí±â 318È£ |
Critical care
<ÁÂÀå: ¾Èö¹Î>
|
|||
14:00~14:25 | ECMO | ±è¼®Âù | °¡Å縯ÀÇ´ë | |
14:25~14:50 | Ventilator associated pneumonia | Á¶¿µÀç | ¼¿ïÀÇ´ë | |
14:50~15:15 | Rapid response system | ¼Áö¿µ | ¼º±Õ°üÀÇ´ë | |
<ÁÂÀå: °íÀ±¼®>
|
||||
15:15~15:40 | ARDS, new definition and treatment | ÀÌ»ó¹Î | ¼¿ïÀÇ´ë | |
15:40~16:05 | Lung ultrasound | ÇÏ¿µ·Ï | ºÐ´çÁ¦»ýº´¿ø, ÀÀ±ÞÀÇÇаú |
|
16:05~16:30 | Ventilator weaning | ÀÓ丸 | ¿ï»êÀÇ´ë | |
¾Ë·¹¸£±â 317È£ |
Perspectives on diagnosis and treatment of allergic diseases
<ÁÂÀå: ÃÖº´ÈÖ>
|
|||
14:00~14:40 | Chronic refractory cough: diagnostic approach and treatment | À̺´Àç | ¼º±Õ°üÀÇ´ë | |
14:40~15:20 | Drug allergy: pharmacogentic markers | ±è¹ÎÇý | ÀÌÈÀÇ´ë | |
<ÁÂÀå: ÃÖµ¿Ã¶>
|
||||
15:20~16:00 | Inhaler technique: challenge for drug delivery | Á¤Àç¿ø | ÀÎÁ¦ÀÇ´ë | |
16:00~16:40 | Food allergy: emerging therapies | °í¿µÀÏ | Àü³²ÀÇ´ë |
ºÐ°ú | ½Ã°£ | ±³À°ÁÖÁ¦ | ¼º¸í | ¼Ò¼Ó |
---|---|---|---|---|
½ÅÀå 318È£ |
Organ cross-talk and interaction
<ÁÂÀå: ÀÓõ±Ô>
|
|||
08:30~09:10 | Cardiorenal syndrome | ¹ÚÁ¾ÇÏ | ¿ï»êÀÇ´ë | |
09:10~09:50 | Hepatorenal syndrome | ÀåÇý·Ã | ¼º±Õ°üÀÇ´ë | |
<ÁÂÀå: 䵿¿Ï>
|
||||
09:50~10:30 | Kidney-lung cross-talk | °í°Áö | °í·ÁÀÇ´ë | |
10:30~11:10 | Kidney-brain cross-talk | ±è¼º±Õ | ÇѸ²ÀÇ´ë | |
·ù¸¶Æ¼½º 318È£ |
Update of rheumatic diseases
<ÁÂÀå: ¼ÛÁ¤¼ö>
|
|||
13:00~13:30 | Treatment of rheumatoid arthritis | ¼ÛÁ¤½Ä | ¿¬¼¼ÀÇ´ë | |
13:30~14:00 | Treatment of lupus nephritis | ¼ºÀ±°æ | ÇѾçÀÇ´ë | |
14:00~14:30 | Treatment of soft tissue rheumatism | ÀÌÀçÁØ | ¼º±Õ°üÀÇ´ë | |
14:30~15:00 | break | |||
<ÁÂÀå: Â÷ÈƼ®>
|
||||
15:00~15:30 | Vasculitis and behcet disease | ÀÓ¹ÌÁø | ÀÎÇÏÀÇ´ë | |
15:30~16:00 | Psoriatic arthritis | ½Å±âö | ¼¿ïÀÇ´ë |
ºÐ°ú | ½Ã°£ | ±³À°ÁÖÁ¦ | ¼º¸í | ¼Ò¼Ó |
---|---|---|---|---|
¼Òȱâ 318È£ |
Current issues in gastroenterology & hepatology
<ÁÂÀå: ÀÌÁ¤ÀÏ, ±èÁøÈ«>
|
|||
13:30~13:50 | Diagnosis of helicobacter pylori infection in chronic atrophic gastritis | À̼±¿µ | °Ç±¹ÀÇ´ë | |
13:50~14:10 | Update on refractory gastroesophageal reflux disease | Á¤Çý°æ | ÀÌÈÀÇ´ë | |
14:10~14:30 | Eliminating interval colon cancer | ¹Úµ¿ÀÏ | ¼º±Õ°üÀÇ´ë | |
14:30~14:50 | Optimal management of IBD patients | Á¤¼º¾Ö | ÀÌÈÀÇ´ë | |
14:50~15:10 | Diagnosis and management strategy of pancreatic cystic lesions | ·ùÁö°ï | ¼¿ïÀÇ´ë | |
15:10~15:30 | Idiopathic pancreatitis: how to approach | õ¿µ±¹ | °Ç±¹ÀÇ´ë | |
15:30~15:50 | State of the art treatment for chronic hepatitis B | ±èÁöÈÆ | °í·ÁÀÇ´ë | |
15:50~16:10 | State of the art treatment for chronic hepatitis C | Á¤¿ìÁø | °è¸íÀÇ´ë |
ºÐ°ú | ½Ã°£ | ±³À°ÁÖÁ¦ | ¼º¸í | ¼Ò¼Ó |
---|---|---|---|---|
½ÉÀå 300È£ |
Update of cardiovascular disease management
<ÁÂÀå: ±èÀçÇü>
|
|||
08:30~08:55 | Past, present, and future of medical therapy in ischemic heart disease | È«¿µÁØ | Àü³²ÀÇ´ë | |
08:55~09:20 | Past, present, and future of PAD treatment | ³ª½Â¿î | °í·ÁÀÇ´ë | |
09:20~09:45 | Practical issues in novel oral anticoagulant therapy in atrial fibrillation | Á¤º¸¿µ | ¿¬¼¼ÀÇ´ë | |
09:45~10:10 | Management of acute heart failure | ÀÌÇØ¿µ | ¼¿ïÀÇ´ë | |
10:10~10:35 | Update of recent guidelines including korean guideline | ±èÁ¾Áø | °æÈñÀÇ´ë | |
10:35~11:00 | Update of valvular heart disease treatment | ÀÌ»óö | ¼º±Õ°üÀÇ´ë | |
³»ºÐºñ-´ë»ç 301È£ |
Up-to-date topics in clinical endocrinology
<ÁÂÀå: ¹ÚÁ¤Çö>
|
|||
08:30~09:10 | The clinical implications of vitamin D supplementation | È«Àº°æ | ÇѸ²ÀÇ´ë | |
09:10~09:50 | The positioning of novel anti-hyperglycemic agents in type 2 diabetes management | ¿ø±ÔÀå | ¿µ³²ÀÇ´ë | |
09:50~10:30 | Controversies in the diagnosis and the management of thyroid nodules | °È£Ã¶ | Àü³²ÀÇ´ë | |
10:30~11:10 | The successful long-term treatment of hypopituitarism | ±èµ¿¼± | ÇѾçÀÇ´ë | |
°¨¿° 307È£ |
Update in enteric syndromes caused by infectious agents
<ÁÂÀå: ¹èÇöÁÖ>
|
|||
08:30~09:10 | Clostridium difficile; Challenge in molecular epidemiology, diagnostic technlogy and antimicrobial resistance |
±èÈñÁ¤ | ¿¬¼¼ÀÇ´ë, Áø´Ü°Ë»çÀÇÇаú |
|
09:10~09:50 | Non-typhoidal salmonellosis; what is new in clinic & lab | ¿ìÈïÁ¤ | ÇѸ²ÀÇ´ë | |
<ÁÂÀå: ¹é°æ¶õ>
|
||||
09:50~10:30 | Reemerging hepatitis a in Korea & host immune response | ½Å¼Ò¿¬ | °üµ¿ÀÇ´ë | |
10:30~11:10 | Unrecognized parasitic enteritis in Korea: developed country settings | Çã¼± | ÇѸ²ÀÇ´ë, ±â»ýÃæÇаú |
* ºÐ°úÀü¹®ÀÇ¿¬¼ö±³À° ÆòÁ¡ : ºÐ°úÀü¹®ÀÇ¿¬¼ö±³À° ¹× ³»°úÀü¹®ÀÇ Æò»ý±³À° °¢ 3ÆòÁ¡
|